New Drug Rules Aim To Speed Generics
President Bush today announced new regulations to hasten the pace at which generic drugs are brought to market, a measure the administration says will save $3.5 billion annually after it takes effect Aug. 18.
RNAi Firms Stake Their Claims First there was gene splicing. Next came monoclonal antibodies. And now, RNA interference, or gene silencing, has taken the scientific community by storm. Reportedly, RNA interference technology has revolutionized the practice of molecular biology – and the excitement it has generated continues to mount
More U.S. Investment in Biotech Needed, USAID Chief Says The United States and the international community should continue to invest more in the development of new agricultural technologies — including biotechnology — to prevent millions more Africans from becoming malnourished and vulnerable to disease and infection, says Andrew Natsios, administrator of the U.S. Agency for International Development (USAID).
Biotech Investors: When Will They Ever Learn?
Investors should get a grip on reality. Many small companies that were lifted on the latest news are strapped for cash and pursuing risky science that will take years to bear fruit. Even for big players, good trial data on a drug don’t guarantee Food & Drug Administration approval. And once drugs do get approved, most of them face competition in the market.